Elekta Reports Mixed Full-Year Results Amid R&D Impairment

Swedish medical technology firm Elekta reported a net loss of 381 million Swedish Kronor for its fourth quarter, impacted by a 1.064 billion Swedish Kronor non-cash impairment from discontinued research and development projects, the company said.

For the full year, net income fell to 240 million Swedish Kronor.

Despite this, net sales in constant exchange rates rose 6% in the fourth quarter to 5.156 billion Swedish Kronor, driven by Europe and APAC.

The company achieved its best Q4 gross margin in five years at 40.3% and generated strong cash flow of 1.248 billion Swedish Kronor.

Elekta expects year-over-year net sales growth and expanding margins, according to the company.